Metastatic mechanisms in follicular cell-derived thyroid cancer

Endocrine-Related Cancer

Volumn 20, Issue 6, 2013, Pages

  Phay, John E ^a   Ringel, Matthew D ^b  

^a Department of Surgery   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; Metastases; Metastases suppressors; Thyroid carcinoma; Tumor stem cells

Indexed keywords

SUNITINIB;

ANAPLASTIC THYROID CANCER; CANCER STEM CELL; HUMAN; METASTASIS; NONHUMAN; QUALITY OF LIFE; REVIEW; THYROID CANCER; THYROID CARCINOMA;

ANGIOGENESIS; METASTASES; METASTASES SUPPRESSORS; THYROID CARCINOMA; TUMOR STEM CELLS;

ADENOCARCINOMA, FOLLICULAR; ANIMALS; HUMANS; NEOPLASM METASTASIS;

EID: 84891445532     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0187     Document Type: Review

References (131)

1. Aguirre-Ghiso JA 2007 Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews. Cancer 7 834-846. (doi:10.1038/ nrc2256)
2. Antonica F, Kasprzyk DF, Opitz R, Iacovino M, Liao XH, Dumitrescu AM, Refetoff S, Peremans K, Manto M, Kyba M et al. 2012 Generation of functional thyroid from embryonic stem cells. Nature 491 66-71. (doi:10.1038/nature11525)
3. Arai T, Watanabe M, Onodera M, Yamashita T, Masunaga A, Itoyama S, Itoh K& Sugawara I 1993 Reduced nm23-H1 messenger RNA expression in metastatic lymph nodes from patients with papillary carcinoma of the thyroid. American Journal of Pathology 142 1938-1944.
4. Arai T, Yamashita T, Urano T, Masunaga A, Itoyama S, Itoh K, Shiku H & Sugawara I 1995 Preferential reduction of nm23-H1 gene product in metastatic tissues from papillary and follicular carcinomas of the thyroid. Modern Pathology 8 252-256.
5. Arufe MC, Lu M, Kubo A, Keller G, Davies TF & Lin RY 2006 Directed differentiation of mouse embryonic stem cells into thyroid follicular cells. Endocrinology 147 3007-3015. (doi:10.1210/en.2005-1239)
6. Baccelli I & Trumpp A 2012 The evolving concept of cancer and metastasis stem cells. Journal of Cell Biology 198 281-293. (doi:10.1083/jcb. 201202014)
7. Baek KH, Zaslavsky A, Lynch RC, Britt C, Okada Y, Siarey RJ, Lensch MW, Park IH, Yoon SS,Minami T et al. 2009 Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature 459 1126-1130. (doi:10.1038/nature08062)
8. Baker EL, Bonnecaze RT & Zaman MH 2009 Extracellular matrix stiffness and architecture govern intracellular rheology in cancer. Biophysical Journal 97 1013-1021. (doi:10.1016/j.bpj.2009.05.054)
9. Barkan D, Green JE & Chambers AF 2010 Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. European Journal of Cancer 46 1181-1188. (doi:10.1016/j.ejca.2010.02.027)
10. Black WC & Welch HG 1993 Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. New England Journal of Medicine 328 1237-1243. (doi:10.1056/ NEJM199304293281706)
11. Borrello MG, Alberti L, Fischer A, Degl'innocenti D, Ferrario C, Gariboldi M, Marchesi F, Allavena P, Greco A, Collini P et al. 2005 Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. PNAS 102 14825-14830. (doi:10.1073/pnas. 0503039102)
12. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML et al. 2010 The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467 1109-1113. (doi:10.1038/nature09460)
13. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J et al. 2009 Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Research 69 1302-1313. (doi:10. 1158/0008-5472.CAN-08-2741)
14. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J et al. 2010 Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clinical Cancer Research 16 45-55. (doi:10.1158/1078-0432.CCR-09-1630)
15. Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH, Chen DT, Tai LK, Yung MC, Chang SC et al. 2009 Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochemical and Biophysical Research Communications 385 307-313. (doi:10.1016/j.bbrc.2009.05.048)
16. Chute JP, Muramoto GG, Whitesides J, Colvin M, Safi R, Chao NJ & McDonnell DP 2006 Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. PNAS 103 11707-11712. (doi:10.1073/pnas.0603806103)
17. Coclet J, Foureau F, Ketelbant P, Galand P & Dumont JE 1989 Cell population kinetics in dog and human adult thyroid. Clinical Endocrinology 31 655-665. (doi:10.1111/j.1365-2265.1989.tb01290.x)
18. Comen EA 2012 Tracking the seed and tending the soil: evolving concepts in metastatic breast cancer. Discovery Medicine 14 97-104.
19. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA & Allan AL 2009 High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. Journal of Cellular and Molecular Medicine 13 2236-2252. (doi:10.1111/j.1582- 4934.2008.00455.x)
20. Davies TF, Latif R, Minsky NC & Ma R 2011 Clinical review: the emerging cell biology of thyroid stem cells. Journal of Clinical Endocrinology and Metabolism 96 2692-2702. (doi:10.1210/jc.2011-1047)
21. Dumont JE, Lamy F, Roger P & Maenhaut C 1992 Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiological Reviews 72 667-697.
22. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F et al. 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. Journal of Clinical Endocrinology and Metabolism 91 2892-2899. (doi:10.1210/ jc.2005-2838)
23. Dwight T, Thoppe SR, Foukakis T, Lui WO, Wallin G, Hoog A, Frisk T, Larsson C & Zedenius J 2003 Involvement of the PAX8/peroxisome proliferator-Activated receptor gamma rearrangement in follicular thyroid tumors. Journal of Clinical Endocrinology and Metabolism 88 4440-4445. (doi:10.1210/jc.2002-021690)
24. Ebos JM & Pili R 2012 Mind the gap: potential for rebounds during antiangiogenic treatment breaks. Clinical Cancer Research 18 3719-3721. (doi:10.1158/1078-0432.CCR-12-1459)
25. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG & Kerbel RS 2009 Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 232-239. (doi:10.1016/ j.ccr.2009.01.021)
26. Espinosa AV, Shinohara M, Porchia LM, Chung YJ, McCarty S, Saji M & Ringel MD 2009 Regulator of calcineurin 1 modulates cancer cell migration in vitro. Clinical & Experimental Metastasis 26 517-526. (doi:10.1007/s10585- 009-9251-1)
27. Evans MJ & Kaufman MH 1981 Establishment in culture of pluripotential cells from mouse embryos. Nature 292 154-156. (doi:10.1038/ 292154a0)
28. Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, Tan TG, Zheng L, Ong LC, Jin Y et al. 2010 Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. Journal of Clinical Investigation 120 2030-2039. (doi:10.1172/JCI42002)
29. Facciabene A, Motz GT & Coukos G 2012 T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Research 72 2162-2171. (doi:10.1158/0008-5472.CAN-11-3687)
30. Farrar JD, Katz KH, Windsor J, Thrush G, Scheuermann RH, Uhr JW & Street NE 1999 Cancer dormancy. VII. A regulatory role for CD8CT cells and IFN-gamma in establishing and maintaining the tumor-dormant state. Journal of Immunology 162 2842-2849.
31. Ferrara N 2002 VEGF and the quest for tumour angiogenesis factors. Nature Reviews. Cancer 2 795-803. (doi:10.1038/nrc909)
32. Fierabracci A, Puglisi MA, Giuliani L, Mattarocci S & Gallinella-Muzi M 2008 Identification of an adult stem/progenitor cell-like population in the human thyroid. Journal of Endocrinology 198 471-487. (doi:10.1677/ JOE-07-0552)
33. Folkman J 1971 Tumor angiogenesis: therapeutic implications. New England Journal of Medicine 285 1182-1186. (doi:10.1056/ NEJM197108122850711)
34. Folkman J & Kalluri R 2004 Cancer without disease. Nature 427 787. (doi:10.1038/427787a)
35. French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP & Haugen BR 2010 Tumor-Associated lymphocytes and increased FoxP3Cregulatory T cell frequency correlate with more aggressive papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 95 2325-2333. (doi:10.1210/jc.2009-2564)
36. French JD, Kotnis GR, Said S, Raeburn CD, McIntyre RC Jr, Klopper JP & Haugen BR 2012 Programmed death-1CT cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 97 E934-E943. (doi:10.1210/jc.2011-3428)
37. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P et al. 2012 Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine 366 883-892. (doi:10. 1056/NEJMoa1113205)
38. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S et al. 2007 ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1 555-567. (doi:10.1016/j.stem. 2007.08.014)
39. Guarino V, CastelloneMD, Avilla E & Melillo RM 2010 Thyroid cancer and inflammation.Molecular and Cellular Endocrinology 321 94-102. (doi:10. 1016/j.mce.2009.10.003)
40. Hadfield G 1954 The dormant cancer cell. BMJ 2 607-610. (doi:10.1136/ bmj.2.4888.607)
41. Hanahan D & Weinberg RA 2011 Hallmarks of cancer: the next generation. Cell 144 646-674. (doi:10.1016/j.cell.2011.02.013)
42. Harach HR, Franssila KO & Wasenius VM 1985 Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A systematic autopsy study. Cancer 56 531-538. (doi:10.1002/1097-0142(19850801)56:3! 531::AID-CNCR2820560321O3.0.CO;2-3)
43. Hasle H, Clemmensen IH & MikkelsenM2000 Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 355 165-169. (doi:10.1016/S0140-6736(99)05264-2)
44. Haugen BR & Sherman SI 2013 Evolving approaches to patients with advanced differentiated thyroid cancer. Endocrine Reviews 34 439-455. (doi:10.1210/er.2012-1038)
45. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ & Heeschen C 2007 Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1 313-323. (doi:10.1016/j.stem.2007.06.002)
46. Horak CE, Lee JH, Marshall JC, Shreeve SM & Steeg PS 2008 The role of metastasis suppressor genes in metastatic dormancy. APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica 116 586-601. (doi:10.1111/j.1600- 0463.2008.01027.x)
47. Husemann Y,Geigl JB, Schubert F, Musiani P, MeyerM, Burghart E, Forni G, Eils R, Fehm T, Riethmuller G et al. 2008 Systemic spread is an early step in breast cancer. Cancer Cell 13 58-68. (doi:10.1016/j.ccr.2007.12.003)
48. Hynes RO 2009 The extracellular matrix: not just pretty fibrils. Science 326 1216-1219. (doi:10.1126/science.1176009)
49. IiizumiM, Bandyopadhyay S & Watabe K 2007 Interaction of Duffy antigen receptor for chemokines andKAI1: a critical stepinmetastasis suppression. Cancer Research 67 1411-1414. (doi:10.1158/0008-5472.CAN-06-3801)
50. Jankovic B, Le KT & Hershman JM 2013 Clinical review: Hashimoto's thyroiditis and papillary thyroid carcinoma: is there a correlation? Journal of Clinical Endocrinology and Metabolism 98 474-482. (doi:10.1210/jc.2012-2978)
51. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA et al. 2009 Aldehyde dehydrogenase 1 is a tumor stem cellassociated marker in lung cancer. Molecular Cancer Research 7 330-338. (doi:10.1158/1541- 7786.MCR-08-0393)
52. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L & Massague J 2009 Tumor self-seeding by circulating cancer cells. Cell 139 1315-1326. (doi:10.1016/j.cell.2009.11.025)
53. Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ & Sherman SI 2013 Clinical responses to Vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF mutation. Thyroid 23 1277-1283. (doi:10.1089/thy.2013.0057)
54. Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O,Mimura T, Ito K & Tanaka S 1999 Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. Journal of Clinical Endocrinology and Metabolism 84 4043-4049. (doi:10.1210/jc.84.11.4043)
55. Klein CA 2011 Framework models of tumor dormancy from patient-derived observations. Current Opinion in Genetics & Development 21 42-49. (doi:10.1016/j.gde.2010.10.011)
56. Klein M, Vignaud JM, Hennequin V, Toussaint B, Bresler L, Plenat F, Leclere J, Duprez A & Weryha G 2001 Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 86 656-658. (doi:10.1210/jc.86.2.656)
57. Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH & Riethmuller G 2002 Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360 683-689. (doi:10.1016/S0140-6736(02)09838-0)
58. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ & Schreiber RD 2007 Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450 903-907. (doi:10.1038/nature06309)
59. Krock BL, Skuli N & Simon MC 2011 Hypoxia-induced angiogenesis: good and evil. Genes & Cancer 2 1117-1133. (doi:10.1177/ 1947601911423654)
60. Kubota Y 2012 Tumor angiogenesis and anti-Angiogenic therapy. Keio Journal of Medicine 61 47-56. (doi:10.2302/kjm.61.47)
61. Kusumbe AP & Bapat SA 2009 Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Research 69 9245-9253. (doi:10.1158/0008-5472. CAN-09-2802)
62. Lan L, Cui D, Nowka K & DerwahlM2007 Stem cells derived from goiters in adults form spheres in response to intense growth stimulation and require thyrotropin for differentiation into thyrocytes. Journal of Clinical Endocrinology and Metabolism 92 3681-3688. (doi:10.1210/jc.2007-0281)
63. Lee JH, Kim Y, Choi JW & Kim YS 2013 The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-Analysis. European Journal of Endocrinology 168 343-349. (doi:10. 1530/EJE-12-0903)
64. Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, Blair E, Francis GL & Tuttle RM 2001 Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129 552-558. (doi:10.1067/msy.2001.112592)
65. Lin RY 2011 Thyroid cancer stem cells. Nature Reviews. Endocrinology 7 609-616. (doi:10.1038/nrendo.2011.127)
66. Lin RY, Kubo A, Keller GM & Davies TF 2003 Committing embryonic stem cells to differentiate into thyrocyte-like cells in vitro. Endocrinology 144 2644-2649. (doi:10.1210/en.2002-0122)
67. Lloyd RV, Hardin H, Montemayor-Garcia C, Rotondo F, Syro LV, Horvath E & Kovacs K 2013 Stem cells and cancer stem-like cells in endocrine tissues. Endocrine Pathology 24 1-10. (doi:10.1007/s12022-013-9235-1)
68. Longmire TA, Ikonomou L, Hawkins F, Christodoulou C, Cao Y, Jean JC, Kwok LW, Mou H, Rajagopal J, Shen SS et al. 2012 Efficient derivation of purified lung and thyroid progenitors from embryonic stem cells. Cell Stem Cell 10 398-411. (doi:10.1016/j.stem.2012.01.019)
69. Ma R, Latif R & Davies TF 2009 Thyrotropin-independent induction of thyroid endoderm from embryonic stem cells by activin A. Endocrinology 150 1970-1975. (doi:10.1210/en.2008-1374)
70. Malanchi I, Santamaria-Martinez A, Susanto E, PengH, Lehr HA, Delaloye JF & Huelsken J 2012 Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481 85-89. (doi:10.1038/ nature10694)
71. Marino N, Nakayama J, Collins JW & Steeg PS 2012 Insights into the biology and prevention of tumor metastasis provided by the Nm23 metastasis suppressor gene. Cancer Metastasis Reviews 31 593-603. (doi:10.1007/s10555-012- 9374-8)
72. Marshall JC, Collins JW, Nakayama J, Horak CE, Liewehr DJ, Steinberg SM, Albaugh M, Vidal-Vanaclocha F, Palmieri D, Barbier Met al. 2012 Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. Journal of the National Cancer Institute 104 1306-1319. (doi:10.1093/jnci/djs319)
73. Mazzaferri EL & Kloos RT 2001 Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. Journal of Clinical Endocrinology and Metabolism 86 1447-1463. (doi:10.1210/jc. 86.4.1447)
74. McCarty SK, Saji M, Zhang X, Jarjoura D, Fusco A, Vasko VV & Ringel MD 2010Group I p21-Activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion. Endocrine-Related Cancer 17 989-999. (doi:10.1677/ERC-10-0168)
75. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D et al. 2004 Circulating tumor cells in patients with breast cancer dormancy. Clinical Cancer Research 10 8152-8162. (doi:10.1158/1078-0432.CCR-04-1110)
76. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M, Ghossein RA, Rosen N & Fagin JA 2013 Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discovery 3 520-533. (doi:10.1158/2159-8290.CD-12-0531)
77. Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F & Pantel K 2005 Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clinical Cancer Research 11 3678-3685. (doi:10.1158/1078-0432.CCR-04-2469)
78. Muzio G, Maggiora M, Paiuzzi E, Oraldi M & Canuto RA 2012 Aldehyde dehydrogenases and cell proliferation. Free Radical Biology & Medicine 52 735-746. (doi:10.1016/j.freeradbiomed.2011.11.033)
79. Muzza M, Degl'Innocenti D, Colombo C, Perrino M, Ravasi E, Rossi S, Cirello V, Beck-Peccoz P, Borrello MG & Fugazzola L 2010 The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clinical Endocrinology 72 702-708. (doi:10.1111/j.1365-2265.2009.03699.x)
80. Nash KT, Phadke PA, Navenot J-M, Hurst DR, Accavitti-Loper MA, Sztul E, Vaidya KS, Frost AR, Kappes JX, Peiper SC et al. 2007 Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. Journal of the National Cancer Institute 99 309-321. (doi:10.1093/jnci/djk053)
81. Nguyen DX, Bos PD & Massague J 2009 Metastasis: from dissemination to organ-specific colonization. Nature Reviews. Cancer 9 274-284. (doi:10.1038/nrc2622)
82. NielsenM, Thomsen JL, Primdahl S, Dyreborg U & Andersen JA 1987 Breast cancer and atypia among young and middle-Aged women: a study of 110 medicolegal autopsies. British Journal of Cancer 56 814-819. (doi:10.1038/bjc.1987.296)
83. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG & Nikiforov YE 2002 PAX8-PPAR gamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. American Journal of Surgical Pathology 26 1016-1023. (doi:10.1097/00000478-200208000-00006)
84. Nixon IJ, Whitcher MM, Palmer FL, Tuttle RM, Shaha AR, Shah JP, Patel SG & Ganly I 2012 The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 22 884-889. (doi:10.1089/thy.2011.0535)
85. Nowicki TS, Kummer NT, Iacob C, Suslina N, Schaefer S, Schantz S, Shin E, Moscatello AL, Tiwari RK & Geliebter J 2010 Inhibition of uPAR and uPA reduces invasion in papillary thyroid carcinoma cells. Laryngoscope 120 1383-1390. (doi:10.1002/lary.20915)
86. Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E et al. 2010 B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. PNAS 107 10649-10654. (doi:10.1073/pnas.1004934107)
87. O'Connell JT, SugimotoH, Cooke VG, MacDonald BA, Mehta AI, LeBleu VS, Dewar R, Rocha RM, Brentani RR, Resnick MB et al. 2011 VEGF-A and Tenascin-C produced by S100A4C stromal cells are important for metastatic colonization. PNAS 108 16002-16007. (doi:10.1073/pnas. 1109493108)
88. Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, Terao Y, Kumano S, Takatsu Y, Masuda Y et al. 2001 Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 411 613-617. (doi:10.1038/35079135)
89. Oleinika K, Nibbs RJ, Graham GJ & Fraser AR 2013 Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clinical and Experimental Immunology 171 36-45. (doi:10.1111/j.1365-2249. 2012.04657.x)
90. Oskarsson T & Massague J 2012 Extracellular matrix players in metastatic niches. EMBO Journal 31 254-256. (doi:10.1038/emboj.2011.469)
91. Paget S 1889 The distribution of secondary growths in cancer of the breasts. Lancet 1 571-573. (doi:10.1016/S0140-6736(00)49915-0)
92. Pantel K, Brakenhoff RH & Brandt B 2008 Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nature Reviews. Cancer 8 329-340. (doi:10.1038/nrc2375)
93. Peter HJ, Gerber H, Studer H & Smeds S 1985 Pathogenesis of heterogeneity in human multinodular goiter. A study on growth and function of thyroid tissue transplanted onto nude mice. Journal of Clinical Investigation 76 1992-2002. (doi:10.1172/JCI112199)
94. Podsypanina K, Du YC, Jechlinger M, Beverly LJ, Hambardzumyan D & Varmus H 2008 Seeding and propagation of untransformed mouse mammary cells in the lung. Science 321 1841-1844. (doi:10.1126/ science.1161621)
95. Reis-Filho JS, Preto A, Soares P, Ricardo S, Cameselle-Teijeiro J & Sobrinho- Simoes M 2003 p63 expression in solid cell nests of the thyroid: further evidence for a stem cell origin. Modern Pathology 16 43-48. (doi:10.1097/01.MP.0000047306.72278.39)
96. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM et al. 2009 Mutational profile of advanced primary and metastatic radioactive iodinerefractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Research 69 4885-4893. (doi:10.1158/ 0008-5472.CAN-09-0727)
97. Ringel MD 2011 Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier. Thyroid 21 487-492. (doi:10.1089/thy.2011.2121)
98. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A,BasuD,GimottyP,VogtT&HerlynM2010Atemporarily distinct subpopulation of slow-cyclingmelanoma cells is required for continuous tumor growth. Cell 141 583-594. (doi:10.1016/j.cell.2010.04.020)
99. Rosenberg SA 2012 Raising the bar: the curative potential of human cancer immunotherapy. Science Translational Medicine 4 127ps128. (doi:10.1126/ scitranslmed.3003634)
100. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA & Fagin JA 2008 Increased density of tumor-Associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocrine-Related Cancer 15 1069-1074. (doi:10.1677/ERC-08-0036)
101. RyderM,Gild M, Hohl TM, Pamer E, Knauf J, Ghossein R, Joyce JA&Fagin JA 2013 Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-Associated macrophages and impairs BRAF-induced thyroid cancer progression. PLoS ONE 8 e54302. (doi:10.1371/journal.pone. 0054302)
102. Sabra M, Dominguez J, Grewal R, Larson S, Ghossein R, Tuttle R & Fagin J 2013 Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-Avid distant metastases. Journal of Clinical Endocrinology and Metabolism 98 E829-E836. (doi:10.1210/jc.2012-3933)
103. SakrWA,Grignon DJ,Haas GP,Schomer KL, Heilbrun LK,Cassin BJ, Powell J, Montie JA, Pontes JE & Crissman JD 1995 Epidemiology of high grade prostatic intraepithelial neoplasia. Pathology, Research and Practice 191 838-841. (doi:10.1016/S0344-0338(11)80965-9)
104. Sampieri K & Fodde R 2012 Cancer stem cells and metastasis. Seminars in Cancer Biology 22 187-193. (doi:10.1016/j.semcancer.2012.03.002)
105. Sarlis NJ 2000 Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects. Reviews in Endocrine & Metabolic Disorders 1 183-196. (doi:10.1023/A:1010079031162)
106. Schardt JA, Meyer M, Hartmann CH, Schubert F, Schmidt-Kittler O, Fuhrmann C, Polzer B, Petronio M, Eils R & Klein CA 2005 Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 8 227-239. (doi:10. 1016/j.ccr.2005.08.003)
107. Schreiber RD, Old LJ & SmythMJ 2011 Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331 1565-1570. (doi:10.1126/science.1203486)
108. Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL & Haugen BR 2009 Inhibition of Src with AZD0530 reveals the Src-focal adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. Journal of Clinical Endocrinology and Metabolism 94 2199-2203. (doi:10.1210/jc.2008-2511)
109. Shaik S, Nucera C, Inuzuka H, Gao D, Garnaas M, Frechette G, Harris L, Wan L, Fukushima H, Husain A et al. 2012 SCF(b-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. Journal of Experimental Medicine 209 1289-1307. (doi:10.1084/jem.20112446)
110. Sherman SI 2009 Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. Journal of Clinical Endocrinology and Metabolism 94 1493-1499. (doi:10.1210/jc.2008-0923)
111. Smallridge RC, Marlow LA & Copland JA 2009 Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocrine-Related Cancer 16 17-44. (doi:10.1677/ERC-08-0154)
112. Sosa MS, Avivar-Valderas A, Bragado P, Wen HC & Aguirre-Ghiso JA 2011 ERK1/2 and p38a/b signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clinical Cancer Research 17 5850-5857. (doi:10.1158/1078-0432.CCR-10-2574)
113. Stathatos N, Bourdeau I, Espinosa AV, Saji M, Vasko VV, Burman KD, Stratakis CA & Ringel MD 2005 KiSS-1/G protein-coupled receptor 54 metastasis suppressor pathway increases myocyte-enriched calcineurin interacting protein 1 expression and chronically inhibits calcineurin activity. Journal of Clinical Endocrinology and Metabolism 90 5432-5440. (doi:10.1210/jc.2005-0963)
114. Steeg PS, Bevilacqua G, Pozzatti R, Liotta LA & Sobel ME 1988 Altered expression of NM23, a gene associated with low tumor metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis. Cancer Research 48 6550-6554.
115. StraumeO,Shimamura T,LampaMJ,CarreteroJ,OyanAM,JiaD,BorgmanCL, SoucherayM,Downing SR, Short SMet al. 2012 Suppression of heat shock protein 27 induces long-termdormancy in human breast cancer. PNAS 109 8699-8704. (doi:10.1073/pnas.1017909109)
116. Takano T 2007 Fetal cell carcinogenesis of the thyroid: theory and practice. Seminars in Cancer Biology 17 233-240. (doi:10.1016/j.semcancer.2006. 02.001)
117. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML & Fusco A 1998 RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clinical Cancer Research 4 287-294.
118. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS & Jones JM 1998 Embryonic stem cell lines derived from human blastocysts. Science 282 1145-1147. (doi:10.1126/science.282. 5391.1145)
119. Thomas T, Nowka K, Lan L&DerwahlM2006 Expression of endoderm stem cell markers: evidence for the presence of adult stem cells in human thyroid glands. Thyroid 16 537-544. (doi:10.1089/thy.2006.16.537)
120. Thomas D, Friedman S & Lin RY 2008 Thyroid stem cells: lessons from normal development and thyroid cancer. Endocrine-Related Cancer 15 51-58. (doi:10.1677/ERC-07-0210)
121. Todaro M, Iovino F, Eterno V, Cammareri P, Gambara G, Espina V, Gulotta G, Dieli F, Giordano S, De Maria R et al. 2010 Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Research 70 8874-8885. (doi:10.1158/0008-5472.CAN-10-1994)
122. Trepel M, Arap W & Pasqualini R 2002 In vivo phage display and vascular heterogeneity: implications for targeted medicine. Current Opinion in Chemical Biology 6 399-404. (doi:10.1016/S1367-5931(02)00336-8)
123. Uhr JW & Pantel K 2011 Controversies in clinical cancer dormancy. PNAS 108 12396-12400. (doi:10.1073/pnas.1106613108)
124. Valent P, Bonnet D, Wohrer S, Andreeff M, Copland M, Chomienne C & Eaves C 2013 Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. Cancer Research 73 1037-1045. (doi:10.1158/0008-5472. CAN-12-3678)
125. Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la Chapelle A et al. 2007 Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. PNAS 104 2803-2808. (doi:10. 1073/pnas.0610733104)
126. Willis RA 1934 The Spread of Tumours in the Human Body. London, UK: J. & A. Churchill.
127. WuX, Northcott PA, Dubuc A, DupuyAJ, ShihDJ, Witt H, Croul S, Bouffet E, Fults DW, Eberhart CG et al. 2012a Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 482 529-533. (doi:10.1038/nature10825)
128. Wu Y, Jiang W, Wang Y, Wu J, Saiyin H, Qiao X, Mei X, Guo B, Fang X, Zhang L et al. 2012b Breast cancer metastasis suppressor 1 regulates hepatocellular carcinoma cell apoptosis via suppressing osteopontin expression. PLoS ONE 7 e42976. (doi:10.1371/journal.pone.0042976)
129. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA et al. 2010 Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467 1114-1117. (doi:10.1038/nature09515)
130. Zafon C, Obiols G, CastellvI J, Tallada N, Galofre P, Gemar E, Mesa J & Simo R 2001 nm23-H1 immunoreactivity as a prognostic factor in differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 86 3975-3980. (doi:10.1210/jc.86.8.3975)
131. Zaman MH, Trapani LM, Sieminski AL, Mackellar D, Gong H, Kamm RD, Wells A, Lauffenburger DA & Matsudaira P 2006 Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell- matrix adhesion and proteolysis. PNAS 103 10889-10894. (doi:10.1073/pnas.0604460103)